Zymeworks ZYME Other drug supply — Research and development collaborations
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's other drug supply — research and development collaborations.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's other drug supply — research and development collaborations?
- Zymeworks (ZYME) reported other drug supply — research and development collaborations of $117K in Q1 2026.
- How has Zymeworks's other drug supply — research and development collaborations changed year-over-year?
- Zymeworks's other drug supply — research and development collaborations decreased by 94.6% year-over-year, from $2.15M to $117K.
- What does other drug supply — research and development collaborations mean?
- This metric represents revenue recognized from research and development collaboration agreements specifically associated with the company's drug supply or platform service offerings. It reflects the financial value derived from partnerships where the company provides specialized biotherapeutic development capabilities or clinical supply support to third-party collaborators. Tracking this revenue stream helps investors assess the commercial viability of the company's proprietary technology platforms and the strength of its strategic partnership model.